Invested in Speeding Innovation

Building 302 – Lilly’s Small Molecule Design and Development (SMDD) Facility

Building 302 was designed as an innovation hub for Lilly Research Laboratories in our hometown of Indianapolis, Indiana. This research and development center features laboratories that facilitate multi-disciplinary collaboration, where researchers utilize advanced technologies to accelerate the development of new medicines across our five therapeutic areas – diabetes, oncology, neurodegeneration, immunology and pain. The facility will focus its efforts on small molecules and synthetic peptides, which currently comprise about half of Lilly's clinical portfolio.

Building 302 at a Glance

  • Adds approximately 130,000 square feet to Lilly’s existing R&D footprint in Indianapolis
  • Features purpose-built labs for chemists, engineers and biologists to collaborate within one space to facilitate joint projects between small- and large-molecule design and development
  • Incorporates several design elements from collaborations with the local Indiana community, including artwork from students and faculty of the Herron School of Art and Design at Indiana University – Purdue University Indianapolis and furniture built by Purposeful Design throughout the space

Locations

Building 302 in Indianapolis

Building 302 Research Labs


People

Dave Ricks

Dave Ricks

Chairman, President and Chief Executive Officer

Low Resolution
Full Size
Dan Skovronsky

Dan Skovronsky

Chief Scientific Officer and President, Lilly Research Laboratories

Low Resolution
Full Size
Anne White

Anne White

Vice President, Next Generation Research and Development

Low Resolution
Full Size

Resources